Related Experiment Videos
T cell defined tumor antigens
B J Van den Eynde1, P van der Bruggen
1Ludwig Institute for Cancer Research, Brussels, Belgium. vandeneynde@licr.ucl.ac.be
Abstract:
T cell defined antigens have now been characterized in a large variety of tumor types, in both mice and humans. An increasing number of these antigens appear to result from tumor-specific mutations, and some of these mutations may be implicated in oncogenesis. The priority is now to demonstrate that immunization against some of these antigens is clinically valuable for antitumor therapy, and the first results of clinical pilot studies are now emerging.
Insights
Researchers are identifying tumor antigens resulting from specific mutations. Early clinical trials are now exploring the potential of immunizing against these antigens for effective antitumor therapy.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- T cell-defined tumor antigens are increasingly identified across diverse cancer types in humans and mice.
- A growing subset of these antigens originates from tumor-specific mutations, some potentially driving cancer development (oncogenesis).
Purpose of the Study:
- To assess the clinical utility of immunizing against tumor-specific antigens for cancer treatment.
- To present emerging data from initial clinical trials evaluating this therapeutic approach.
Main Methods:
- Characterization of T cell-defined antigens in various tumor models.
- Analysis of tumor-specific mutations linked to antigen presentation.
- Conducting and analyzing pilot clinical studies for antitumor immunotherapy.
Main Results:
- A wide range of tumor antigens has been identified.
- Tumor-specific mutations are a significant source of these antigens.
- Initial clinical pilot studies are yielding preliminary results on therapeutic efficacy.
Conclusions:
- T cell-defined antigens, particularly those arising from tumor mutations, represent promising targets for cancer immunotherapy.
- Further clinical investigation is warranted to validate the therapeutic potential of antigen-specific immunization in cancer patients.